Profound Medical (PROF) 6-K Profound Medical Announces Second Quarter 2022 Financial Results

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2022

Commission File Number: 001-39032

PROFOUND MEDICAL CORP.
(Translation of registrant's name into English)

2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [   ]      Form 40-F [ X ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

EXHIBIT INDEX

The following document is attached as an exhibit hereto and is incorporated by reference herein:  

Exhibit	Title
99.1	Press Release dated August 4, 2022
99.2	Interim Condensed Consolidated Financial Statements
99.3	Management’s Discussion and Analysis
99.4	Form 52 – 109F2 – Certification of Interim Filings – CEO
99.5	Form 52 – 109F2 – Certification of Interim Filings – CFO

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PROFOUND MEDICAL CORP.
	(Registrant)
Date: August 4, 2022	/s/ Rashed Dewan
	Rashed Dewan
	Chief Financial Officer